Idiopathic pulmonary fibrosis (IPF), the most common phenotype of IIPs, has a prognosis that is influenced by a number of ...

The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

Incitec has announced plans to sell its Gibson Island site in Brisbane, and cease making single super in Geelong amid plans to divest its fertiliser division. ..Read More ...

Pliant Therapeutics (PLRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said Michael ...

Walker announced earlier in the month that he was retiring from radio after 58 years due to ill health, having been previously diagnosed with idiopathic pulmonary fibrosis (IPF). After playing Johnny ...

Se og Hor reported a sighting of the royal boarding a flight from Gardermoen to London at 1pm with Marius Borg Høiby, 27, who ...

Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life. Delays in treatment can result in advanced disease stages, reduced treatment ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsMichael Castagna - CEOChris Prentiss ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...

Despite a rise in net loss, Trevi Therapeutics Inc (TRVI) advances in clinical trials and maintains a strong cash position to ...